FCPLJ treatment downregulated several inflammatory cytokine genes in the liver, including CCL6/MRP-1, CCL8/MCP-2, CCL12/MCP-5, CCL17/TARC, IL1R1, IL1RN/IL1Ra, NAMPT/PBEF1, and PF4/CXCL4, indicating its potential role in mitigating inflammation during infection [139]. This evidence concerns the gene CCL17 and infection.